Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) on August 10. The company’s shares closed last Friday at $6.71.
Devarakonda covers the Healthcare sector, focusing on stocks such as Verastem, Edgewise Therapeutics, and Affimed. According to TipRanks, Devarakonda has an average return of -15.4% and a 18.42% success rate on recommended stocks.
Edgewise Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.00, a 287.48% upside from current levels. In a report released on August 10, RBC Capital also maintained a Buy rating on the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Edgewise Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $21.47 million. In comparison, last year the company had a GAAP net loss of $16.07 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Read More on EWTX:
